Aktuellt
SENASTE
Redeye is encouraged to learn that the ongoing SAN711 phase I study (n=80), now in the MAD (”multiple ascending dose”) phase, is progressing as planned and that the readout still is expected to take place by Q2 this year. We are currently reviewing our take on Saniona and will return with a research update within a month, most likely in close connection to the year-end report.
LÄS MER
